Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.
Ten patients with Parkinson's disease and urinary symptoms underwent urodynamic assessments before and after subcutaneous administration of the dopamine receptor agonist apomorphine. Voiding efficiency improved after apomorphine injection, with an increase in mean and maximum flow rates in nine patients and reduction in post-micturition residual volume in six. Although the effect on detrusor behaviour was variable, subcutaneous apomorphine may be of use in both the assessment and treatment of voiding dysfunction in patients with Parkinson's disease.
Christmas
T J
TJ
Department of Urology, Middlesex Hospital, London.
Kempster
P A
PA
Chapple
C R
CR
Frankel
J P
JP
Lees
A J
AJ
Stern
G M
GM
Milroy
E J
EJ
D000328:Adult; D000368:Aged; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects; D004294:Domperidone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D001743:Urinary Bladder / Q000502:physiology; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
D004294:Domperidone; D001058:Apomorphine